Skip to search formSkip to main contentSkip to account menu
Myocardial reperfusion injury.
TLDR
This review focuses on the mechanisms of the injury, on attempts to protect the heart against it, and on promising new approaches to cardioprotection during percutaneous coronary intervention.
View on PubMed
Myocardial ischemia-reperfusion injury: a neglected therapeutic target.
TLDR
A number of new therapeutic strategies currently under investigation for preventing myocardial reperfusion injury have the potential to improve clinical outcomes in patients with acute MI treated with PPCI.
View on PubMed
New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway.
View on PubMed
Inhibiting Mitochondrial Fission Protects the Heart Against Ischemia/Reperfusion Injury
TLDR
Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury, suggesting a novel pharmacological strategy for cardioprotection.
View on Wolters Kluwer
Postconditioning: A Form of “Modified Reperfusion” Protects the Myocardium by Activating the Phosphatidylinositol 3-Kinase–Akt Pathway
TLDR
It is shown for the first time that ischemic Postcond protects the myocardium by activating the prosurvival kinases PI3K–Akt, eNOS, and p70S6K in accordance with the RISK pathway.
View on Wolters Kluwer
Ischemic preconditioning protects by activating prosurvival kinases at reperfusion.
TLDR
The reperfusion phase following sustained ischemia plays an essential role in mediating IPC-induced protection and it is demonstrated that IPC protects the heart by phosphorylating the prosurvival kinases Akt and ERK-1/2 at reperfusions.
View on PubMed
Survival kinases in ischemic preconditioning and postconditioning.
View on PubMed
Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance.
View on PubMed
Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection
TLDR
The administration of pharmacological agents which are known to activate the RISK pathway, when applied as adjuvant therapy to current myocardial reperfusion strategies for patients presenting with an AMI, should lead to improved clinical outcomes in this patient group.
View on Springer
Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial
View on Elsevier
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License